Recommendations for the use of Rituximab in neuromyelitis optica spectrum disorders - 19/04/18

Doi : 10.1016/j.neurol.2017.11.005

J. Ciron ^a,^b,^⁎ , B. Audoin ^c,^d, B. Bourre ^e, D. Brassat ^a,^f, F. Durand-Dubief ^g, D. Laplaud ^h, E. Maillart ⁱ, C. Papeix ⁱ, S. Vukusic ^g,^j,^k, H. Zephir ^l, R. Marignier ^g,^m,^{^{1
Dr Collongues and Dr Marignier contributed equally to the work.}}, N. Collongues ^n,^o,^p,^{^{1
Dr Collongues and Dr Marignier contributed equally to the work.}}
on behalf of the
NOMADMUS group, under the aegis of OFSEP, SFSEP
^a Pôle de neurosciences, department of neurology, hôpital Pierre-Paul-Riquet, university hospital of Toulouse, place du Dr-Baylac, 31059 Toulouse Cedex 9, France
^b Pôle neurosciences locomoteur, department of neurology, university hospital of Poitiers, 2, rue de la Milétrie, 86021 Poitiers Cedex, France
^c Pôle de neurosciences cliniques, department of beurology, hôpital de la Timone, AP–HM, 13005 Marseille, France
^d CNRS, CRMBM UMR 7339, Aix-Marseille University, 13005 Marseille, France
^e Department of neurology, university hospital of Rouen, 76000 Rouen, France
^f UMR 1043, University Toulouse III, 31400 Toulouse, France
^g Department of neurology, Sclérose en Plaques, pathologies de la myéline et neuro-inflammation, hôpital neurologique Pierre-Wertheimer, hospices civils de Lyon, 69677 Lyon, France
^h Department of neurology, university hospital of Nantes, 44093 Nantes, France
ⁱ Department of neurology, Pitié-Salpêtrière Hospital, AP–HP, 75013 Paris, France
^j Inserm U1028 CNRS UMR 5292, Observatoire français de la Sclérose en Plaques, centre des neurosciences de Lyon, 69003 Lyon, France
^k University Lyon 1, 69003 Lyon, France
^l Department of neurology, university hospital of Lille, 59037 Lille, France
^m Inserm U1028 CNRS UMR 5292, FLUID Team, faculté de médecine Laennec, centre de recherche en neurosciences de Lyon, 69008 Lyon, France
ⁿ Department of neurology, university hospital of Strasbourg, 67200 Strasbourg, France
^o Clinical Investigation Center, Inserm U1434, university hospital of Strasbourg, 67200 Strasbourg, France
^p Biopathology of Myelin, neuroprotection and therapeutic Strategies, Inserm U1119, university hospital of Strasbourg, 67200 Strasbourg, France

^⁎Corresponding author.Pôle de neurosciences, department of neurology, hôpital Pierre-Paul-Riquet, university hospital of Toulouse, place du Dr-Baylac, 31059 Toulouse cedex 9, France

connettersi o creare un account

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
Articolo gratuito.

Si connetta per beneficiarne

Abstract

There is growing evidence of a preventive effect of Rituximab (RTX) in neuromyelitis optica spectrum disorders (NMO-SD). This monoclonal antibody against CD20 is becoming the most widely used preventive therapy in NMO-SD, as a first-line therapy or as a rescue therapy. Nevertheless, considerable heterogeneity still exists concerning the pre-treatment work-up, the vaccinations required before and under treatment, the number and dosage of infusions, prevention of the risk of infusion-related reactions, prevention of infections under treatment, and frequency of therapeutic cycles. Thanks to a collaborative work among NMO-SD experts belonging to the NOMADMUS project, we provide here recommendations for all these topics concerning RTX use in NMO-SD.

Il testo completo di questo articolo è disponibile in PDF.

Keywords : Neuromyelitis optica, Rituximab, Guidelines, Recommendations, Treatment

Mappa

Introduction

Question 1: work up before starting rituximab

Question 2: vaccinations before starting rituximab and under treatment

Question 3: timing of rituximab start

Question 4: modality of induction treatment by rituximab

Question 5: infectious risk under rituximab and preventive measures

Question 6: monitoring of RTX re-infusion: tools, rate and posology

Question 7: therapeutic combination

Question 8: pregnancy, breastfeeding

Before pregnancy and pregnancy exposed to rituximab

Disclosure of interest

Informations about OFSEP and SFSEP (learned societies)

Esportazione

Vol 174 - N° 4

P. 255-264 - aprile 2018 Ritorno al numero

Articolo precedente

Historical reflections on neurosyphilis based on the 1826 treatise on general paralysis in demented patients by Louis Florentin Calmeil (1798–1895)
F. Macia, Y. Ardagna

| Articolo seguente

Intravascular large B-cell lymphoma mimicking cerebral amyloid angiopathy-related inflammation
L. Leclercq, L. Mechtouff, M. Hermier, T.-H. Cho, N. Nighoghossian, F. Ducray

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.

connettersi o creare un account

Recommendations for the use of Rituximab in neuromyelitis optica spectrum disorders - 19/04/18

Abstract

Mappa

Citazioni Export

File

Contenuto

Il mio account

Aide & support

Dichiarazione CNIL